Patients
I need help with…
Understanding hereditary cancer risk
What is my risk of developing hereditary cancer?
Treating cancer
What are my treatment options?
Prenatal care
Is my baby at risk for a genetic condition?
Managing mental health
How might my genes affect my medication outcomes?
(sidebar parent)
About genetic testing
What are the costs of genetic testing?
Financial assistance
Patient Resources
How does genetic testing work?
Patient record request
Prostate Cancer
What are my treatment options?
Providers
My patient needs a test for…
Assessing hereditary cancer risk
What is my patient’s risk of developing hereditary cancer?
Cancer treatment
What is the best treatment for my patient?
Prenatal care
What is a pregnancy’s risk of genetic disease?
Mental health treatment
How will my patient metabolize or respond to certain medications?
(sidebar parent)
About our tests
Myriad test catalog
Research & whitepapers
MyRisk
®
gene table
Provider resources
Order a test
Order patient materials
Documents & forms
Scope of service & lab certificates
Prostate Cancer Treatment
What are my patient’s treatment options?
Our Tests
Tests for…
(column wrapper)
Prenatal care
Chromosome conditions
Genetic diseases
Cancer risk assessment
Hereditary cancer
Mental health
Depression
Anxiety
ADHD
(column wrapper)
Cancer management
Breast cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Endometrial cancer
Other cancers
All tests
(sidebar parent)
TESTS BY SPECIALTY
Oncology
Urology
Imaging
OB/GYN
Mental Health
Internal/Primary care
All tests
TESTS BY NAME
BRACAnalysis CDx
®
EndoPredict
®
Foresight
®
GeneSight
®
MyChoice
®
CDx
MyRisk
®
(cancer treatment)
MyRisk
®
(cancer risk)
Prequel
®
Precise
™
Tumor
Prolaris
®
About Myriad
Who we are
Our science & innovation
Corporate & social responsibility
Latest news
Myriad Genetics Blog
Corporate information
Our leadership
Patient advocacy partners
Investor relations
Careers
Partnerships
Companion diagnostics
ORDER
Search:
Order
Search:
Patients
I need help with…
Understanding hereditary cancer risk
What is my risk of developing hereditary cancer?
Treating cancer
What are my treatment options?
Prenatal care
Is my baby at risk for a genetic condition?
Managing mental health
How might my genes affect my medication outcomes?
(sidebar parent)
About genetic testing
What are the costs of genetic testing?
Financial assistance
Patient Resources
How does genetic testing work?
Patient record request
Prostate Cancer
What are my treatment options?
Providers
My patient needs a test for…
Assessing hereditary cancer risk
What is my patient’s risk of developing hereditary cancer?
Cancer treatment
What is the best treatment for my patient?
Prenatal care
What is a pregnancy’s risk of genetic disease?
Mental health treatment
How will my patient metabolize or respond to certain medications?
(sidebar parent)
About our tests
Myriad test catalog
Research & whitepapers
MyRisk
®
gene table
Provider resources
Order a test
Order patient materials
Documents & forms
Scope of service & lab certificates
Prostate Cancer Treatment
What are my patient’s treatment options?
Our Tests
Tests for…
(column wrapper)
Prenatal care
Chromosome conditions
Genetic diseases
Cancer risk assessment
Hereditary cancer
Mental health
Depression
Anxiety
ADHD
(column wrapper)
Cancer management
Breast cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Endometrial cancer
Other cancers
All tests
(sidebar parent)
TESTS BY SPECIALTY
Oncology
Urology
Imaging
OB/GYN
Mental Health
Internal/Primary care
All tests
TESTS BY NAME
BRACAnalysis CDx
®
EndoPredict
®
Foresight
®
GeneSight
®
MyChoice
®
CDx
MyRisk
®
(cancer treatment)
MyRisk
®
(cancer risk)
Prequel
®
Precise
™
Tumor
Prolaris
®
About Myriad
Who we are
Our science & innovation
Corporate & social responsibility
Latest news
Myriad Genetics Blog
Corporate information
Our leadership
Patient advocacy partners
Investor relations
Careers
Partnerships
Companion diagnostics
News Releases
Categories:
All Categories
Corporate
Products
Pipeline
Financial
Mar 02, 2023
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Products
Mar 01, 2023
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
Products
Feb 28, 2023
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
Financial
Feb 22, 2023
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
Financial
Feb 09, 2023
Myriad Genetics to Participate in Upcoming Healthcare Conferences
Financial
Feb 07, 2023
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
Products
Jan 05, 2023
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
Products
Jan 04, 2023
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
Corporate
Dec 19, 2022
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
Corporate
Dec 08, 2022
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
Products
Nov 29, 2022
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Products
Nov 17, 2022
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Products
Nov 14, 2022
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
Products
Nov 10, 2022
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
Products
Nov 03, 2022
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Products
Next page